Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
11.07. | Lexeo Therapeutics: Aktie schnellt nach Fair-Value-Signal um 96 % in die Höhe | 3 | Investing.com Deutsch | ||
07.07. | Lexeo Therapeutics: FDA erteilt "Breakthrough"-Status für Gentherapie - Aktie im Plus | - | Investing.com Deutsch | ||
07.07. | Stifel bestätigt Kaufempfehlung für Lexeo Therapeutics nach positivem FDA-Bescheid | 5 | Investing.com Deutsch | ||
07.07. | Stifel reiterates Buy rating on Lexeo Therapeutics stock at $21 price target | 2 | Investing.com | ||
07.07. | Why Lexeo Is Rising In Pre-market? | 1 | RTTNews | ||
07.07. | FDA grants breakthrough therapy designation to Lexeo's FA treatment | 1 | Investing.com | ||
07.07. | Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia | 2 | GlobeNewswire (USA) | ||
30.06. | Lexeo Therapeutics-Aktionäre wählen Direktoren und bestätigen Wirtschaftsprüfer bei Jahresversammlung | 1 | Investing.com Deutsch | ||
LEXEO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
30.06. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
24.06. | Lexeo to help launch spinout around RNA drugs for the heart | 1 | BioPharma Dive | ||
24.06. | Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics | 1 | GlobeNewswire (USA) | ||
13.06. | Lexeo Therapeutics files to sell 41.63M shares of common stock for holders | 1 | Seeking Alpha | ||
27.05. | Leerink senkt Kursziel für Lexeo Therapeutics auf 10 US-Dollar, behält Ausblick bei | 1 | Investing.com Deutsch | ||
27.05. | Leerink cuts Lexeo Therapeutics price target to $10, maintains outlook | 1 | Investing.com | ||
27.05. | Lexeo Therapeutics raises $80M in private placement | 2 | Seeking Alpha | ||
27.05. | Lexeo Therapeutics Announces $80 Mln Private Placement Of Shares | - | RTTNews | ||
27.05. | Lexeo Therapeutics secures $80 million in private placement | 1 | Investing.com | ||
27.05. | Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases | 2 | GlobeNewswire (USA) | ||
27.05. | Lexeo Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
16.05. | Lexeo stock price target cut to $15 by H.C. Wainwright | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SANGAMO THERAPEUTICS | 0,439 | +1,32 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
AVID BIOSERVICES | 12,100 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 05.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.02.2025ISIN NameCA75525M1095 RAZOR... ► Artikel lesen | |
PROTALIX BIOTHERAPEUTICS | 1,250 | 0,00 % | Protalix BioTherapeutics Inc. Q1 Loss Narrows | JERUSALEM (dpa-AFX) - Protalix BioTherapeutics Inc. (PLX) released Loss for first quarter of -$3.62 millionThe company's earnings came in at -$3.62 million, or -$0.05 per share. This compares... ► Artikel lesen | |
ENZO BIOCHEM | 0,580 | 0,00 % | Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction | Transaction Follows Completion of Comprehensive Strategic Review by Special Committee of the Board to Maximize Shareholder Value Farmingdale, NY, June 24, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc.... ► Artikel lesen | |
QUANTERIX | 5,360 | -2,72 % | Quanterix entlässt Führungskräfte bei Akoya-Tochter und rechnet mit Kosten von 3,3 Millionen US-Dollar | ||
BELITE BIO | 51,50 | 0,00 % | Belite Bio, Inc: Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy | - 500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia SAN DIEGO, July 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc.... ► Artikel lesen | |
QIAGEN | 41,405 | -0,35 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
NUVALENT | 83,40 | -2,67 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
IMMUNOVANT | 17,910 | -2,02 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen | |
EVOTEC | 7,456 | +0,59 % | Evotec, Hugo Boss, Lanxess, Nagarro, SMA Solar, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,845 | +5,89 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
SUMMIT THERAPEUTICS | 26,200 | -5,18 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
BIONTECH | 94,40 | -2,13 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 33,740 | -0,88 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
ARVINAS | 7,350 | -5,34 % | Arvinas Inc.: Arvinas Announces Retirement of Chief Executive Officer and Succession Plan | - John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor - - Dr. Houston to Remain Chairperson of Arvinas Board of Directors... ► Artikel lesen |